Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Toffoli

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Endocrine|July 17, 2024
Copeptin in obese and nonobese pregnant womenFederica Tonon, Barbara Toffoli, Tamara Stampalija, et al.
International Journal of Molecular Sciences|June 12, 2026
Retrospective Comparative Study of Oral Versus Subcutaneous Semaglutide in Patients with Type 2 Diabetes MellitusBarbara Toffoli, Matteo Michieletto, Stella Bernardi, et al.
Biomed Research International|May 21, 2016
Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular DiseaseStella Bernardi, Fleur Bossi, Barbara Toffoli, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 3, 2010
Prevention of accelerated atherosclerosis by AT1 receptor blockade in experimental renal failureStella Bernardi, Riccardo Candido, Barbara Toffoli, et al.
Mediators of Inflammation|January 11, 2017
Dyslipidemia and Diabetes Increase the OPG/TRAIL Ratio in the Cardiovascular SystemBarbara Toffoli, Bruno Fabris, Giacomo Bartelloni, et al.
Current Pharmaceutical Design|June 26, 2012
Potential role of TRAIL in the management of autoimmune diabetes mellitusStella Bernardi, Alessia Norcio, Barbara Toffoli, et al.
FEBS Open Bio|February 15, 2019
Renal mineralocorticoid receptor expression is reduced in lipoatrophyBarbara Toffoli, Stella Bernardi, Carine Winkler, et al.
Investigational New Drugs|January 4, 2011
TRAIL shows potential cardioprotective activityBarbara Toffoli, Stella Bernardi, Riccardo Candido, et al.
Acta Diabetologica|April 26, 2013
The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40Paola Secchiero, Barbara Toffoli, Elisabetta Melloni, et al.
Cell Death & Disease|November 18, 2021
TRAIL/DR5 pathway promotes AKT phosphorylation, skeletal muscle differentiation, and glucose uptakeBarbara Toffoli, Federica Tonon, Veronica Tisato, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Endocrine|July 17, 2024
Copeptin in obese and nonobese pregnant womenFederica Tonon, Barbara Toffoli, Tamara Stampalija, et al.
International Journal of Molecular Sciences|June 12, 2026
Retrospective Comparative Study of Oral Versus Subcutaneous Semaglutide in Patients with Type 2 Diabetes MellitusBarbara Toffoli, Matteo Michieletto, Stella Bernardi, et al.
Biomed Research International|May 21, 2016
Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular DiseaseStella Bernardi, Fleur Bossi, Barbara Toffoli, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 3, 2010
Prevention of accelerated atherosclerosis by AT1 receptor blockade in experimental renal failureStella Bernardi, Riccardo Candido, Barbara Toffoli, et al.
Mediators of Inflammation|January 11, 2017
Dyslipidemia and Diabetes Increase the OPG/TRAIL Ratio in the Cardiovascular SystemBarbara Toffoli, Bruno Fabris, Giacomo Bartelloni, et al.
Current Pharmaceutical Design|June 26, 2012
Potential role of TRAIL in the management of autoimmune diabetes mellitusStella Bernardi, Alessia Norcio, Barbara Toffoli, et al.
FEBS Open Bio|February 15, 2019
Renal mineralocorticoid receptor expression is reduced in lipoatrophyBarbara Toffoli, Stella Bernardi, Carine Winkler, et al.
Investigational New Drugs|January 4, 2011
TRAIL shows potential cardioprotective activityBarbara Toffoli, Stella Bernardi, Riccardo Candido, et al.
Acta Diabetologica|April 26, 2013
The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40Paola Secchiero, Barbara Toffoli, Elisabetta Melloni, et al.
Cell Death & Disease|November 18, 2021
TRAIL/DR5 pathway promotes AKT phosphorylation, skeletal muscle differentiation, and glucose uptakeBarbara Toffoli, Federica Tonon, Veronica Tisato, et al.
Pageof 5